메뉴 건너뛰기
European Radiology
Volumn 23, Issue 3, 2013, Pages 632-639
Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies
Author keywords

Choi response criteria; CT; Metastatic renal cell cancer; Prognostic factors; RECIST
Indexed keywords

ANGIOGENESIS INHIBITOR; EVEROLIMUS; IODIXANOL; IOPROMIDE; SORAFENIB; SUNITINIB; TEMSIROLIMUS;
EID: 84878618268     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-012-2640-x     Document Type: Article
Times cited : (29)
References (15)
  • 1
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    • 19097774 10.1016/j.ejca.2008.10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D
    • Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247
    • (2009) Eur J Cancer , vol.45 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3
  • 2
    • 34249085905 scopus 로고    scopus 로고
    • Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
    • 17470865 10.1200/JCO.2006.07.3049
    • Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759
    • (2007) J Clin Oncol , vol.25 , pp. 1753-1759
    • Choi, H.1    Charnsangavej, C.2    Faria, S.C.3
  • 4
    • 0033526386 scopus 로고    scopus 로고
    • Rising incidence of renal cell cancer in the United States
    • 10235157 10.1001/jama.281.17.1628 1:STN:280:DyaK1M3kvFagtA%3D%3D
    • Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr (1999) Rising incidence of renal cell cancer in the United States. JAMA 281:1628-1631
    • (1999) JAMA , vol.281 , pp. 1628-1631
    • Chow, W.H.1    Devesa, S.S.2    Warren, J.L.3    Fraumeni, Jr.J.F.4
  • 5
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • 17215530 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D
    • Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 6
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • 17215529 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D
    • Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 7
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
    • 18653228 10.1016/S0140-6736(08)61039-9 1:CAS:528:DC%2BD1cXps1GmsLY%3D
    • Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 8
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • 17538086 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D
    • Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281
    • (2007) N Engl J Med , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 9
    • 61349116156 scopus 로고    scopus 로고
    • EORTC-GU group expert opinion on metastatic renal cell cancer
    • 19157861 10.1016/j.ejca.2008.12.010
    • de Reijke TM, Bellmunt J, van Poppel H, Marreaud S, Aapro M (2009) EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 45:765-773
    • (2009) Eur J Cancer , vol.45 , pp. 765-773
    • De Reijke, T.M.1    Bellmunt, J.2    Van Poppel, H.3    Marreaud, S.4    Aapro, M.5
  • 10
    • 84878603912 scopus 로고    scopus 로고
    • Development Core Team R
    • R Foundation for Statistical Computing Vienna
    • Development Core Team R (2011) R: A Language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
    • (2011) R: A Language and Environment for Statistical Computing
  • 11
    • 74749099130 scopus 로고    scopus 로고
    • Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: Importance of size and attenuation on contrast-enhanced CT
    • 20028918 10.2214/AJR.09.2941
    • Smith AD, Lieber ML, Shah SN (2010) Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 194:157-165
    • (2010) AJR Am J Roentgenol , vol.194 , pp. 157-165
    • Smith, A.D.1    Lieber, M.L.2    Shah, S.N.3
  • 12
    • 77953236472 scopus 로고    scopus 로고
    • Morphology, Attenuation, Size, and Structure (MASS) criteria: Assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy
    • 20489085 10.2214/AJR.09.3456
    • Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM (2010) Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 194:1470-1478
    • (2010) AJR Am J Roentgenol , vol.194 , pp. 1470-1478
    • Smith, A.D.1    Shah, S.N.2    Rini, B.I.3    Lieber, M.L.4    Remer, E.M.5
  • 13
    • 77649272736 scopus 로고    scopus 로고
    • Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
    • 20145618 10.1038/sj.bjc.6605567
    • van der Veldt AAM, Meijerink MR, van den Eertwegh AJM, Haanen JB, Boven E (2010) Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 102:803-809
    • (2010) Br J Cancer , vol.102 , pp. 803-809
    • Van Der Veldt, A.A.M.1    Meijerink, M.R.2    Van Den Eertwegh, A.J.M.3    Haanen, J.B.4    Boven, E.5
  • 14
    • 0032865983 scopus 로고    scopus 로고
    • Tumour angiogenesis and its relation to contrast enhancement on computed tomography: A review
    • 10452718 10.1016/S0720-048X(99)00012-1 1:STN:280:DyaK1MznvFOrtQ%3D%3D
    • Miles KA (1999) Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol 30:198-205
    • (1999) Eur J Radiol , vol.30 , pp. 198-205
    • Miles, K.A.1
  • 15
    • 0033778716 scopus 로고    scopus 로고
    • Application of CT in the investigation of angiogenesis in oncology
    • 11048881 10.1016/S1076-6332(00)80632-7 1:STN:280:DC%2BD3crgtFCnuw%3D%3D
    • Miles KA, Charnsangavej C, Lee FT, Fishman EK, Horton K, Lee TY (2000) Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 7:840-850
    • (2000) Acad Radiol , vol.7 , pp. 840-850
    • Miles, K.A.1    Charnsangavej, C.2    Lee, F.T.3    Fishman, E.K.4    Horton, K.5    Lee, T.Y.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.